Human Pathology
Volume 36, Issue 5 , Pages 522-530 , May 2005

Overexpression of laminin-5 γ2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor, and human epidermal growth factor 2

  • Keijiro Kiyoshima, MD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Yoshinao Oda, MD, PhD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
    • Corresponding Author InformationCorresponding authors.
    • ,
  • Naoko Kinukawa, PhD

      Affiliations

    • Department of Medical Information Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Seiji Naito, MD, PhD

      Affiliations

    • Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • Masazumi Tsuneyoshi, MD, PhD

      Affiliations

    • Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan
    • Corresponding Author InformationCorresponding authors.

Received 24 August 2004 ,Accepted 8 February 2005.

References 

  1. Research Group for Population-based Cancer Registries in Japan. Cancer incidence and incidence rates in Japan in 1998: estimates based on data from 12 population-based cancer registries. Jpn J Clin Oncol. 2003;33:241–245
  2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer. 2001;94:153–156
  3. In:  Eble JN,  Sauter G,  Epstein JI, et al. editor. World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC Press; 2004;p. 89–120
  4. Messing EM. Urothelial tumors of the urinary tract. In:  Walsh PC,  Retik AB,  Vaughan ED,  Wein AJ editor. Campbell's urology. 8th ed.. Philadelphia: Saunders; 2002;p. 2743
  5. Sobin LH, Wittekind CH. In: TNM classification of malignant tumors. 5th ed.. New York: Wiley-Liss; 1997;p. 187–190
  6. Timpl R. Structure and biological activity of basement membrane proteins. Eur J Biochem. 1989;180:487–502
  7. Colognato H, Yurchenco PD. Form and function: the laminin family of heterodimers. Dev Dyn. 2000;218:213–234
  8. Moriya Y, Niki T, Yamada T, et al. Increased expression of laminin-5 and its prognostic significance in lung adenocarcinomas of small size: an immunohistochemical analysis of 102 cases. Cancer. 2001;91:1129–1141
  9. Giannelli G, Falk-Marzillier J, Schiraldi O, et al. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science. 1997;277:225–228
  10. Koshikawa N, Giannelli G, Cirulli V, et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol. 2000;148:615–624
  11. Pyke C, Salo S, Ralfkiær E, et al. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res. 1995;55:4132–4139
  12. Soini Y, Määttä M, Salo S, et al. Expression of the laminin gamma 2 chain in pancreatic adenocarcinoma. J Pathol. 1996;180:290–294
  13. Ono Y, Nakanishi Y, Ino Y, et al. Clinicopathologic significance of laminin-5 gamma2 chain expression in squamous cell carcinoma of the tongue: immunohistochemical analysis of 67 lesions. Cancer. 1999;85:2315–2321
  14. Koshikawa N, Moriyama K, Takamura H, et al. Overexpression of laminin gamma2 chain monomer in ivading gastric carcinoma cells. Cancer Res. 1999;59:5596–5601
  15. Hindermann W, Berndt A, Haas KM, et al. Immunohistochemical demonstration of the gamma2 chain of laminin-5 in urinary bladder urothelial carcinoma. Impact for diagnosis and prognosis. Cancer Detec Prev. 2003;27:109–115
  16. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 1996;56:4566–4569
  17. Ristimäki A, Honkanen N, Jänkälä H, et al. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57:1276–1280
  18. Wolff H, Saukkonen K, Anttila S, et al. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998;58:4997–5001
  19. Tucker ON, Dannenberg AJ, Yang EK, et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 1999;59:987–990
  20. Shirahama T, Arima J, Akiba S, et al. Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer. 2001;92:188–193
  21. Kim SL, Kwon SM, Kim YS, et al. Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology. 2002;60:816–821
  22. Shariat SF, Matsumoto K, Kim J, et al. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol. 2003;170:985–989
  23. Niki T, Kohno T, Iba S, et al. Frequent co-localization of COX-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinoma. Am J Pathol. 2002;160:1129–1141
  24. Coffey RJ, Hawkey CJ, Damstrup L, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A. 1997;94:657–662
  25. Mestre JR, Chan G, Zhang F, et al. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer. Ann N Y Acad Sci. 1999;889:62–71
  26. Kiguchi K, Carbajal S, Chan K, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001;61:6971–6976
  27. Endo K, Yoon BI, Pairojkul C, et al. ErbB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002;36:439–450
  28. Mizushima H, Miyagi Y, Kikkawa Y, et al. Differential expression of laminin-5/ladsin subunits in human tissues and cancer cell lines and their induction by tumor promoter and growth factors. J Biochem. 1996;120:1196–1202
  29. Ono Y, Nakanishi Y, Gotoh M, et al. Epidermal growth factor gene amplification is correlated with laminin-5 gamma2 chain expression in oral squamous cell carcinoma cell lines. Cancer Lett. 2002;175:197–204
  30. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor and its ligand transforming growth factor alpha is frequent in resectable non–small cell lung cancer but does not predict tumor progression. Clin Cancer Res. 1997;3:515–522
  31. Gandour-Edwards R, Lara PN, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?. Cancer. 2002;95:1009–1015
  32. Sordat I, Bosman FT, Dorta G, et al. Differential expression of laminin-5 subunits and integrin receptors in human colorectal neoplasia. J Pathol. 1998;185:44–52
  33. Hirosaki T, Mizushima H, Tsubota Y, et al. Structural requirement of carboxyl-terminal globular domains of laminin alpha 3 chain for promotion of rapid cell adhesion and migration by laminin-5. J Biol Chem. 2000;275:22495–22502
  34. Ohno R, Yoshinaga K, Fujita T, et al. Depth of invasion parallels increased cyclooxygenase-2 levels in patients with gastric carcinoma. Cancer. 2001;91:1876–1881
  35. Murata H, Kawano S, Tsuji S, et al. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol. 1999;94:451–455
  36. Achiwa H, Yatabe Y, Hida T, et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res. 1999;5:1001–1005
  37. Khuri FR, Wu H, Lee JJ, et al. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non–small cell lung cancer. Clin Cancer Res. 2001;7:861–867
  38. Ferrandina G, Ranelletti FO, Lauriola L, et al. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and HER-2/neu expression in ovarian cancer. Gynecol Oncol. 2002;85:305–310
  39. Messing EM. Growth factors and bladder cancer: clinical implications of the interactions between growth factors and their urothelial receptors. Semin Surg Oncol. 1992;8:285–292
  40. Neal DE, Mellon K. Epidermal growth factor receptor and bladder cancer: a review. Urol Int. 1992;48:365–371
  41. Thogersen VB, Jorgensen PE, Sorensen BS, et al. Expression of transforming growth factor alpha and epidermal growth factor receptor in human bladder cancer. Scand J Clin Lab Invest. 1992;59:267–277
  42. Jimenez RE, Hussain M, Bianco FJ, et al. HER-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res. 2001;7:2440–2447
  43. Onn A, Correa AM, Gilcrease M, et al. Synchronous overexpression of epidermal growth factor receptor and HER-2–neu protein is a predictor of poor outcome in patients with stage I non–small cell lung cancer. Clin Cancer Res. 2004;10:136–143

PII: S0046-8177(05)00082-1

doi: 10.1016/j.humpath.2005.02.013

Human Pathology
Volume 36, Issue 5 , Pages 522-530 , May 2005

Article Tools

* Image Usage & Resolution